Which has stronger valuation and earnings, MED or LW?

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medifast $385.79M 0.31 -$18.67M -$1.83 N/A Lamb Weston $6.52B 0.95 $357.20M $2.14 20.99

Is MED or LW more profitable?

Lamb Weston has a net margin of 4.61% compared to Medifast's net margin of -5.78%. Lamb Weston's return on equity of 23.77% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Medifast -5.78% -4.80% -3.83% Lamb Weston 4.61% 23.77% 5.76%

Which has preferable valuation and earnings, NOMD or MED?

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nomad Foods $2.99B 0.47 $154.66M $1.03 9.83 Medifast $385.79M 0.31 -$18.67M -$1.83 N/A

Is NOMD or MED more profitable?

Nomad Foods has a net margin of 4.43% compared to Medifast's net margin of -5.78%. Nomad Foods' return on equity of 9.05% beat Medifast's return on equity. Company Net Margins Return on Equity Return on Assets Nomad Foods 4.43% 9.05% 3.61% Medifast -5.78% -4.80% -3.83%

Do analysts rate MED or USNA?

Medifast presently has a consensus target price of $12.00, suggesting a potential upside of 11.52%. Given Medifast's higher probable upside, research analysts clearly believe Medifast is more favorable than USANA Health Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medifast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 USANA Health Sciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer MED or NUS?

Medifast presently has a consensus target price of $12.00, indicating a potential upside of 11.52%. Given Medifast's higher possible upside, equities analysts plainly believe Medifast is more favorable than Nu Skin Enterprises. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medifast 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Nu Skin Enterprises 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Medifast (MED) Competitors

$10.61 -0.41 (-3.72%)

As of 02:52 PM Eastern

Compare

MED vs. LW, NOMD, USNA, NATR, and NUS

Should you buy Medifast stock or one of its competitors? MarketBeat compares Medifast with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medifast include Lamb Weston (LW), Nomad Foods (NOMD), USANA Health Sciences (USNA), Nature's Sunshine Products (NATR), and Nu Skin Enterprises (NUS).

How does Medifast compare to Lamb Weston?

Medifast (NYSE:MED) and Lamb Weston (NYSE:LW) are both consumer staples companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

Medifast presently has a consensus target price of $12.00, suggesting a potential upside of 11.52%. Lamb Weston has a consensus target price of $47.82, suggesting a potential upside of 6.45%. Given Medifast's higher probable upside, analysts plainly believe Medifast is more favorable than Lamb Weston.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lamb Weston	1 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.14

Lamb Weston has a net margin of 4.61% compared to Medifast's net margin of -5.78%. Lamb Weston's return on equity of 23.77% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Lamb Weston	4.61%	23.77%	5.76%

Lamb Weston has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Lamb Weston, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.31	-$18.67M	-$1.83	N/A
Lamb Weston	$6.52B	0.95	$357.20M	$2.14	20.99

Medifast has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Lamb Weston has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market.

95.5% of Medifast shares are held by institutional investors. Comparatively, 89.6% of Lamb Weston shares are held by institutional investors. 3.7% of Medifast shares are held by insiders. Comparatively, 0.3% of Lamb Weston shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Lamb Weston had 6 more articles in the media than Medifast. MarketBeat recorded 6 mentions for Lamb Weston and 0 mentions for Medifast. Lamb Weston's average media sentiment score of 1.30 beat Medifast's score of 0.00 indicating that Lamb Weston is being referred to more favorably in the news media.

Company	Overall Sentiment
Medifast	Neutral
Lamb Weston	Positive

Summary

Lamb Weston beats Medifast on 12 of the 16 factors compared between the two stocks.

How does Medifast compare to Nomad Foods?

Nomad Foods (NYSE:NOMD) and Medifast (NYSE:MED) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Nomad Foods had 7 more articles in the media than Medifast. MarketBeat recorded 7 mentions for Nomad Foods and 0 mentions for Medifast. Nomad Foods' average media sentiment score of 1.14 beat Medifast's score of 0.00 indicating that Nomad Foods is being referred to more favorably in the media.

Company	Overall Sentiment
Nomad Foods	Positive
Medifast	Neutral

75.3% of Nomad Foods shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 17.3% of Nomad Foods shares are owned by insiders. Comparatively, 3.7% of Medifast shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Nomad Foods presently has a consensus target price of $12.50, indicating a potential upside of 23.46%. Medifast has a consensus target price of $12.00, indicating a potential upside of 11.52%. Given Nomad Foods' stronger consensus rating and higher probable upside, equities analysts plainly believe Nomad Foods is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nomad Foods	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Nomad Foods has a net margin of 4.43% compared to Medifast's net margin of -5.78%. Nomad Foods' return on equity of 9.05% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nomad Foods	4.43%	9.05%	3.61%
Medifast	-5.78%	-4.80%	-3.83%

Nomad Foods has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nomad Foods, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nomad Foods	$2.99B	0.47	$154.66M	$1.03	9.83
Medifast	$385.79M	0.31	-$18.67M	-$1.83	N/A

Nomad Foods has a beta of 0.7, meaning that its stock price is 30% less volatile than the broader market. Comparatively, Medifast has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

Nomad Foods beats Medifast on 15 of the 16 factors compared between the two stocks.

How does Medifast compare to USANA Health Sciences?

Medifast (NYSE:MED) and USANA Health Sciences (NYSE:USNA) are both small-cap personal products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

USANA Health Sciences has a net margin of 0.96% compared to Medifast's net margin of -5.78%. USANA Health Sciences' return on equity of 6.21% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
USANA Health Sciences	0.96%	6.21%	4.50%

95.5% of Medifast shares are owned by institutional investors. Comparatively, 54.3% of USANA Health Sciences shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 0.8% of USANA Health Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medifast presently has a consensus target price of $12.00, suggesting a potential upside of 11.52%. Given Medifast's higher probable upside, research analysts clearly believe Medifast is more favorable than USANA Health Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
USANA Health Sciences	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Medifast has a beta of 0.62, suggesting that its stock price is 38% less volatile than the broader market. Comparatively, USANA Health Sciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

USANA Health Sciences has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.31	-$18.67M	-$1.83	N/A
USANA Health Sciences	$925.26M	0.38	$10.76M	$0.47	40.89

In the previous week, USANA Health Sciences had 5 more articles in the media than Medifast. MarketBeat recorded 5 mentions for USANA Health Sciences and 0 mentions for Medifast. USANA Health Sciences' average media sentiment score of 0.23 beat Medifast's score of 0.00 indicating that USANA Health Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Medifast	Neutral
USANA Health Sciences	Neutral

Summary

USANA Health Sciences beats Medifast on 11 of the 14 factors compared between the two stocks.

How does Medifast compare to Nature's Sunshine Products?

Medifast (NYSE:MED) and Nature's Sunshine Products (NASDAQ:NATR) are both small-cap personal products companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

Nature's Sunshine Products has a net margin of 4.06% compared to Medifast's net margin of -5.78%. Nature's Sunshine Products' return on equity of 14.67% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nature's Sunshine Products	4.06%	14.67%	9.27%

95.5% of Medifast shares are owned by institutional investors. Comparatively, 79.4% of Nature's Sunshine Products shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 3.1% of Nature's Sunshine Products shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medifast presently has a consensus target price of $12.00, indicating a potential upside of 11.52%. Nature's Sunshine Products has a consensus target price of $35.00, indicating a potential upside of 68.27%. Given Nature's Sunshine Products' stronger consensus rating and higher probable upside, analysts clearly believe Nature's Sunshine Products is more favorable than Medifast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nature's Sunshine Products	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Nature's Sunshine Products' average media sentiment score of 0.46 beat Medifast's score of 0.00 indicating that Nature's Sunshine Products is being referred to more favorably in the news media.

Company	Overall Sentiment
Medifast	Neutral
Nature's Sunshine Products	Neutral

Nature's Sunshine Products has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nature's Sunshine Products, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.31	-$18.67M	-$1.83	N/A
Nature's Sunshine Products	$489.79M	0.75	$19.52M	$1.10	18.91

Medifast has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market. Comparatively, Nature's Sunshine Products has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

Summary

Nature's Sunshine Products beats Medifast on 13 of the 15 factors compared between the two stocks.

How does Medifast compare to Nu Skin Enterprises?

Medifast (NYSE:MED) and Nu Skin Enterprises (NYSE:NUS) are both small-cap consumer staples companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Nu Skin Enterprises has higher revenue and earnings than Medifast. Medifast is trading at a lower price-to-earnings ratio than Nu Skin Enterprises, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medifast	$385.79M	0.31	-$18.67M	-$1.83	N/A
Nu Skin Enterprises	$1.49B	0.17	$160.20M	$1.10	4.67

Nu Skin Enterprises has a net margin of 3.78% compared to Medifast's net margin of -5.78%. Nu Skin Enterprises' return on equity of 7.47% beat Medifast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medifast	-5.78%	-4.80%	-3.83%
Nu Skin Enterprises	3.78%	7.47%	4.21%

95.5% of Medifast shares are owned by institutional investors. Comparatively, 82.8% of Nu Skin Enterprises shares are owned by institutional investors. 3.7% of Medifast shares are owned by insiders. Comparatively, 2.8% of Nu Skin Enterprises shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Medifast presently has a consensus target price of $12.00, indicating a potential upside of 11.52%. Given Medifast's higher possible upside, equities analysts plainly believe Medifast is more favorable than Nu Skin Enterprises.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medifast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Nu Skin Enterprises	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Nu Skin Enterprises' average media sentiment score of 1.00 beat Medifast's score of 0.00 indicating that Nu Skin Enterprises is being referred to more favorably in the news media.

Company	Overall Sentiment
Medifast	Neutral
Nu Skin Enterprises	Positive

Medifast has a beta of 0.62, indicating that its share price is 38% less volatile than the broader market. Comparatively, Nu Skin Enterprises has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

Summary

Nu Skin Enterprises beats Medifast on 9 of the 13 factors compared between the two stocks.

Get Medifast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MED vs. The Competition

Export

Metric	Medifast	FOOD Industry	Staples Sector	NYSE Exchange
Market Cap	$119.65M	$7.57B	$16.05B	$23.18B
Dividend Yield	N/A	4.11%	3.50%	4.06%
P/E Ratio	-5.88	16.04	25.60	31.12
Price / Sales	0.31	1.24	47.07	20.94
Price / Cash	26.60	9.76	13.22	18.65
Price / Book	0.59	2.80	5.78	4.67
Net Income	-$18.67M	$241.67M	$678.29M	$1.08B
7 Day Performance	-4.80%	-0.84%	-0.85%	-0.99%
1 Month Performance	-14.60%	-1.51%	0.97%	0.24%
1 Year Performance	-18.91%	-13.53%	-12.31%	24.49%

Medifast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MED Medifast	1.4722 of 5 stars	$10.61 -3.7%	$12.00 +13.1%	-21.9%	$117.98M	$385.79M	N/A	870
LW Lamb Weston	4.4556 of 5 stars	$45.27 +0.4%	$47.82 +5.6%	-18.3%	$6.27B	$6.52B	21.16	10,100	Positive News
NOMD Nomad Foods	4.993 of 5 stars	$10.47 +0.9%	$12.50 +19.4%	-41.8%	$1.46B	$2.99B	10.16	7,752	Positive News
USNA USANA Health Sciences	2.439 of 5 stars	$19.94 +0.4%	N/A	-38.1%	$367.60M	$925.26M	42.43	1,570	Analyst Upgrade
NATR Nature's Sunshine Products	3.5359 of 5 stars	$20.51 +0.5%	$35.00 +70.6%	+39.1%	$360.67M	$489.79M	18.65	850

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MED) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medifast (MED) Competitors

MED vs. LW, NOMD, USNA, NATR, and NUS

How does Medifast compare to Lamb Weston?

Summary

How does Medifast compare to Nomad Foods?

Summary

How does Medifast compare to USANA Health Sciences?

Summary

How does Medifast compare to Nature's Sunshine Products?

Summary

How does Medifast compare to Nu Skin Enterprises?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medifast (MED) Competitors

MED vs. LW, NOMD, USNA, NATR, and NUS

How does Medifast compare to Lamb Weston?

Do analysts prefer MED or LW?

Is MED or LW more profitable?

Which has stronger valuation and earnings, MED or LW?

Which has more volatility and risk, MED or LW?

Do institutionals and insiders have more ownership in MED or LW?

Does the media favor MED or LW?

Summary

How does Medifast compare to Nomad Foods?

Does the media refer more to NOMD or MED?

Do institutionals and insiders believe in NOMD or MED?

Do analysts prefer NOMD or MED?

Is NOMD or MED more profitable?

Which has preferable valuation and earnings, NOMD or MED?

Which has more volatility and risk, NOMD or MED?

Summary

How does Medifast compare to USANA Health Sciences?

Is MED or USNA more profitable?

Do institutionals & insiders hold more shares of MED or USNA?

Do analysts rate MED or USNA?

Which has more volatility and risk, MED or USNA?

Which has higher valuation & earnings, MED or USNA?

Does the media prefer MED or USNA?

Summary

How does Medifast compare to Nature's Sunshine Products?

Is MED or NATR more profitable?

Do institutionals and insiders believe in MED or NATR?

Do analysts prefer MED or NATR?

Does the media refer more to MED or NATR?

Which has higher earnings and valuation, MED or NATR?

Which has more volatility and risk, MED or NATR?

Summary

How does Medifast compare to Nu Skin Enterprises?

Which has better valuation & earnings, MED or NUS?

Is MED or NUS more profitable?

Do institutionals and insiders believe in MED or NUS?

Do analysts prefer MED or NUS?

Does the media prefer MED or NUS?

Which has more risk and volatility, MED or NUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MED vs. The Competition

Medifast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools